Radio and PodcastLive Radio & PodcastsOpening Radio and Podcast...
Radio and PodcastLive Radio & PodcastsFetching podcast shows and categories...
Radio and PodcastLive Radio & PodcastsFetching podcast episodes...
New Retina Radio is a place to hear stories about retina that are told nowhere else.
Are patients with DR at higher risk for TDR, DME, vitreous hemorrhage, or blindness based on race or ethnicity ? Jordan Deaner, MD, moderate...
Could GLP-1s originally designed for diabetes and weight loss influence the risk of developing wet AMD? In this episode of New Retina Radio...
In this episode of RetinaLive focused on UNITY® VCS|CS, Jay Sridhar, MD welcomes Steve Charles, MD, FACS, FICS, FASRS and Maria Berrocal, MD...
Co-hosts David Fell, MD, and Justin C. Muste, MD, are joined by Danny Mammo, MD, and Sean Berkowitz, MD, MBA, to talk all things uveitis, in...
Katherine E. Talcott, MD, sits down with retina mentors Yoshihiro Yonekawa, MD, and Adrienne W. Scott, MD, to discuss various strategies men...
How did patients with PDR fare after being lost to follow-up for at least 1 year and then returning to the clinic? Kyle Kovacs, MD, is joine...
Podcast co-hosts David Fell, MD, and Justin Muste, MD, are joined by Joshua H. Uhr, MD, and Arnulfo Garza-Reyes, MD, to share their experien...
Are you ready to accelerate your understanding of retina care?Join Dr. Nemo Patel as he speaks with Dr. Patrick Staropoli, a fellow retina s...
Dr. Nemo Patel is joined by Drs. Sam Minaker and Has Al-khersan, who share lessons learned early in their careers about connecting with pati...
Join Dr. Nemo Patel, Dr. Matthew Donovan, and Dr. Danny Mammo as they share real-world insights on how the next generation of retina special...
What types of delays do Stargardt disease patients experience when it comes to diagnosis? And what are the implications for such delays? Ale...
Podcast co-hosts David Fell, MD, and Justin Muste, MD, sit down with Wills Eye fellow Flavius Beca, MD, to discuss the highs and lows of fel...
How do we know when a retina fellow is truly ready for independent surgery? Nikisha Kothari, MD, moderates a discussion with Jesse Sengillo,...
How should retina specialists integrate next-generation anti-VEGF agents into real-world DME care? In this episode of “Anti-VEGFs: The Next...
How should retina specialists integrate next-generation anti-VEGFs into everyday wet AMD care? In this episode of “Anti-VEGFs: The Next Gene...
Can smarter strategies to tame retinal fluid fluctuations actually improve long-term vision? In episode 3 of this miniseries, host Jay Sridh...
Do retinal fluid fluctuations quietly erode long-term vision? In episode 2 of a 3-part roundtable series, moderator Jay Sridhar, MD joins gu...
In this first episode of a 3-part roundtable series, moderator Jay Sridhar, MD, speaks with David Sarraf, MD, and Danny Mammo, MD, about ret...
How are the world's leading mind on GA management educating patients about GA so they follow-up with their providers? Host Anat Loewenstein,...
At what point in their disease do world-renowned retina specialists want to see patients with GA? Host Anat Loewenstein, MD, leads a candid...
Does antibiotic prophylaxis prior to intravitreal injection affect the risk of endophthalmitis? Join New Retina Radio Journal Club with VBS...
How do you decide when GA patients are ready for complement inhibition—and how do you keep them on therapy in the real world? In episode 3 o...
What do GLP-1 receptor agonists mean for the future of retinal disease? Aleksandra Rachitskaya, MD, joins us to review the ever-evolving dat...
Could a biologic that addresses uveitic macular edema (UME) change the treatment landscape for uveitis patients? Rahul Khurana, MD, joins us...
The dry AMD pipeline is packed. Join New Retina Radio as we break it down with Peter Kaiser, MD, whose podium presentation at AAO 2025 offer...
How do you create clear, durable treatment plans for real-world GA patients? In episode 2 of The Nuts and Bolts of GA Therapy, host Charles...
Could optogenetics represent the innovative thinking needed to restore some function in retinitis pigmentosa (RP) patients? Allen Ho, MD, jo...
How do costs and reimbursements shape practice patterns regarding panretinal photocoagulation (PRP)? Niki Kothari, MD, moderates a discussio...
How do retina specialists first broach the topic of complement inhibition for GA therapy? In episode 1 of this miniseries, moderator Charles...
How should retina specialists reframe their approach to GA therapy? In the final episode of this New Retina Radio miniseries, moderator John...
Should GA therapy start monthly—or is less-than-monthly treatment enough? In episode 3 of this New Retina Radio miniseries, moderator John K...
How do you educate and empower patients to make informed decisions about geographic atrophy (GA) therapy? In episode 2 of this New Retina Ra...
What does it mean to truly keep patients at the center of geographic atrophy (GA) therapy? In this first episode of a four-part New Retina R...
What happens when patients with neovascular age-related macular degeneration (nAMD) show suboptimal response to faricimab (Vabysmo, Genentec...
What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progress...
Time flies: Some wet AMD patients have had the Port Delivery System with Ranibizumab (Susvimo, Genentech/Roche) for more than 5 years. How w...
What happens when two systemic diseases collide? In this episode of New Retina Radio Journal Club with VBS, moderator Lediana Goduni, MD, is...
Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our pre...
The State of Geographic Atrophy Around the Globe: Part 1 of 2 DES: For what pathophysiologic reasons is targeting the complement pathway a v...
Are patients from lower-income households more likely to present with severe diabetic retinopathy (DR)? Ben Young, MD, moderates a discussio...
What do you do when a patient with GA also has wet AMD? And how do you encourage patients on anti-complement therapy to stick with treatment...
How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited f...
What conclusions can be drawn from the LIGHTSITE III study examining photobiomodulation for dry AMD? Moderator Barton Blackorby, MD, sits do...
Duke faculty interview key lecturers from the 2025 Duke AVS Course about their podium talks. Jason Hsu, MD, discusses the best ways to manag...
Faculty from the 2025 Duke AVS Course ask key lecturers to share pearls from their presentations. Lejla Vajzovic, MD, discusses various pedi...
During the 2025 Duke AVS Course, Duke faculty sat down with several key lecturers to discuss their presentations. Avni P. Finn, MD, MBA, dis...
Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results...
Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Mi...
How do GLP-1 drugs influence age-related ocular diseases such as macular degeneration and glaucoma? Moderator Lediana Goduni, MD, is joined...
Questions abound about fellow eye rhegmatogenous retinal detachments (RRD). How often do fellow eye develop RRD after the first one is repai...